Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;32(1):87-90.
doi: 10.1002/pds.5560. Epub 2022 Nov 18.

Understanding the variability of pharmaco-epidemiological studies assessing the risk of appendicitis with mRNA COVID-19 vaccines

Clement Jambon-Barbara  1   2 , Claire Bernardeau  1   2 , Jean-Luc Cracowski  1   2 , Charles Khouri  1   2   3
Affiliations

Understanding the variability of pharmaco-epidemiological studies assessing the risk of appendicitis with mRNA COVID-19 vaccines

Clement Jambon-Barbara et al. Pharmacoepidemiol Drug Saf. 2023 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The author have no conflict of interest related to this study.

Figures

FIGURE 1
FIGURE 1
Forest plot of Incidence Rate of appendicitis in vaccinated and control groups, and Incidence Rate Ratio of appendicitis with mRNA COVID vaccines compared to nonvaccinated.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid‐19 vaccine. N Engl J Med. 2020;383:2603‐2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Research C for BE and COVID‐19 Vaccine Safety Surveillance 2022. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologi....
    1. Barda N, Dagan N, Ben‐Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid‐19 vaccine in a Nationwide setting. N Engl J Med. 2021;385:NEJMoa2110475. doi:10.1056/NEJMoa2110475 - DOI - PMC - PubMed
    1. Kildegaard H, Ladebo L, Andersen JH, et al. Risk of appendicitis after mRNA COVID‐19 vaccination in a Danish population. JAMA Intern Med. 2022;182:684‐686. doi:10.1001/jamainternmed.2022.1222 - DOI - PMC - PubMed
    1. Klein NP, Lewis N, Goddard K, et al. Surveillance for adverse events after COVID‐19 mRNA vaccination. JAMA. 2021;326:1390‐1399. doi:10.1001/jama.2021.15072 - DOI - PMC - PubMed